Abstract
Purpose
Cancer is a disease of the elderly: 60 % of tumours occur in patients aged 65 years or older. Cancer-related fatigue is a common symptom experienced by cancer patients and cancer survivors that profoundly affects all aspects of the quality of life. Although it has been estimated that up to 70 % of elderly with cancer experience fatigue, this symptom is still largely ignored in ageing population.
Methods
We performed a systematic review of the literature identified by MEDLINE.
Results
The relationship between ageing process and pathogenesis of cancer-related fatigue is still not fully understood.
Conclusions
Ageing is associated with an increased prevalence of chronic diseases, decreased functional reserve in multiple organ systems and enhanced susceptibility to stress. Ageing and the concomitant presence of a condition of frailty may predispose to the presence of fatigue. Nevertheless, only few studies have to date specifically assessed the impact of fatigue in the geriatric population. Since cancer-related fatigue is a peculiarly debilitating condition characteristic of elderly cancer patient population, we suggest the early recognition and thorough evaluation of the symptom fatigue, its co-existing causes (i.e. anaemia, mood disorders and sleep disturbances) and co-morbidities (i.e., endocrine disorders, metabolic, cardiovascular and liver diseases).
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00520-013-1897-1/MediaObjects/520_2013_1897_Fig1_HTML.gif)
Similar content being viewed by others
References
Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W (1998) Progress toward guidelines for the management of fatigue. Oncology 12:369–377
Portenoy RK, Itri LM (1999) Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4:1–10
National Comprehensive Cancer Network: Cancer-related fatigue, version 1.2012. http://www.nccn.org/professionals/physicians/PDF/fatigue.pdf. Accessed 4 Apr 2012
de Jong N, Candel MJ, Schouten HC, Abu-Saad HH, Courtens AM (2004) Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol 15:896–905
Prue G, Rankin J, Allen J, Gracey J, Cramp F (2006) Cancer-related fatigue: a critical appraisal. Eur J Cancer 42:846–863
Wu HS, McSweeney M (2007) Cancer-related fatigue: “It’s so much more than just being tired”. Eur J Oncol Nurs 11:117–125
Yavuzsen T, Davis MP, Ranganathan VK, Walsh D, Siemionow V, Kirkova J et al (2009) Cancer-related fatigue: central or peripheral? J Pain Symptom Manage 38:587–596
Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D et al (2008) Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 6:448–455
Kuhnt S, Ernst J, Singer S, Rüffer JU, Kortmann RD, Stolzenburg JU et al (2009) Fatigue in cancer survivors: prevalence and correlates. Onkologie 32:312–317
Giacalone A, Spina M, Berretta M, Tirelli U (2012) Two types of fatigue in cancer patients. BJC 106:424
Curt GA (2001) Fatigue in cancer. Brit Med J 322:1560
Wagner LI, Cella D (2004) Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 91:822–828
Nail LM (2004) My get up and go up and went: fatigue in people with cancer. JNCI Monogr 32:72–75
Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC (2004) Prevalence of anaemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anaemia. Blood 104:2263–2268
Denny SD, Kuchibhatla MN, Cohen HJ (2006) Impact of anaemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 119:327–334
Extermann M, Chen H, Cantor AB, Corcoran MB, Meyer J, Grendys E et al (2002) Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer 38:1466–1473
Balducci L (2010) Anemia, fatigue and aging. Transfus Clin Biol 17:375–381
Mercuriali F, Inghilleri G (2001) Treatment of anaemia in cancer patients: transfusion of rHuEPO. In: Marty M, Pecorelli S (eds) Fatigue and cancer. European School of Oncology Scientific Updates, 5. Elsevier, Amsterdam, pp 185–200
Ferrucci L, Guralnik JM, Woodman RC, Bandinelli S, Lauretani F, Corsi AM et al (2005) Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 118:1288
Nemeth E, Tuttle MS, Powelson J, Donovan A, Ward DM, Ganz T et al (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093
Stabler SP (2008) Prevalence and mechanisms of B12 deficiency. In: Balducci L, Ershler WH, DeGaetano G (eds) Blood disorders in the elderly. University Press, Cambridge, pp 181–191
Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A et al (2006) Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 166:1380–1388
Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J et al. (2009) Erythropoietin or darbepoetin for patients with cancer—meta-analysis based on individual patient data. Cochrane Database Syst Rev CD007303
Raison CL, Miller AH (2003) Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 54:283–294
Mohile SG, Fan L, Reeve E, Mustian K, Peppone L, Janelsins M et al (2011) Association of cancer with geriatric syndromes in older Medicare beneficiaries. J Clin Oncol 29:1458–1464
Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C et al (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-Text Revision), 4th edn. APA, Washington
Cohen-Cole SA, Brown FW, McDaniel JS (1993) Diagnostic assessment of depression in the medically ill. In: Stoudemire A, Fogel B (eds) Psychiatric care of the medical patient. Oxford University Press, New York, pp 53–70
Reuter K, Härter M (2004) The concepts of fatigue and depression in cancer. Eur J Cancer Care 13:127–134
Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PL, Flynn PJ et al (2003) Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Centre Community Clinical Oncology Program. J Clin Oncol 21:4635–4641
Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR et al (2007) Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol 8:603–612
Fiorentino L, Ancoli-Israel S (2006) Insomnia and its treatment in women with breast cancer. Sleep Med Rev 10:419–429
Spiegel K, Leproult R, Van Cauter E (1999) Impact of sleep debt on metabolic and endocrine function. Lancet 354:1435–1439
Caufriez A, Moreno-Reyes R, Leproult R, Vertongen F, Van Cauter E, Copinschi G (2002) Immediate effects of an 8-h advance shift of the rest-activity cycle on 24-h profiles of cortisol. Am J Physiol Endocrinol Metab 282:E1147–E1153
Rao A, Cohen HJ (2004) Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr 32:150–157
Chaudhuri A, Behan PO (2004) Fatigue in neurological disorders. Lancet 363:978–988
Swain MG (2000) Fatigue in chronic disease. Clin Sci 99:1–8
Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121:953–959
Andrews PL, Morrow GR, Hickok JT (2004) Mechanisms and models of fatigue associated with cancer and its treatment: Evidence of pre-clinical and clinical studies. In: Armes J, Krishnasamy M, Higginson I (eds) Fatigue in cancer. Oxford University Press, Oxford, pp 51–87
Fernstrom JD, Fernstrom MH (2006) Exercise, serum free tryptophan, and central fatigue. J Nutr 136:553S–559S
Badawy AA, Morgan CJ, Llewelyn MB, Albuquerque SR, Farmer A (2005) Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J Psychopharmacol 19:385–391
Blomstrand E (2006) A role for branched-chain amino acids in reducing central fatigue. J Nutr 136(2):544S–547S
Newsholme EA, Blomstrand E (1995) Tryptophan, 5-hydroxytryptamine and a possible explanation for central fatigue. Adv Exp Med Biol 384:315–320
Chaouloff F, Elghozi JL, Guezennec Y, Laude D (1985) Effects of conditioned running on plasma, liver and brain tryptophan and on brain 5-hydroxytryptamine metabolism of the rat. Br J Pharmacol 86:33–41
Blomstrand E, Hassmén P, Newsholme EA (1991) Effect of branched-chain amino acid supplementation on mental performance. Acta Physiol Scand 143:225–226
Mittleman KD, Ricci MR, Bailey SP (1998) Branched-chain amino acids prolong exercise during heat stress in men and women. Med Sci Sports Exerc 30:83–91
Strüder HK, Hollmann W, Platen P, Donike M, Gotzmann A, Weber K (1998) Influence of paroxetine, branched-chain amino acids and tyrosine on neuroendocrine system responses and fatigue in humans. Horm Metab Res 30:188–194
Davis JM, Bailey SP (1997) Possible mechanisms of central nervous system fatigue during exercise. Med Sci Sports Exerc 29:45–57
Dinan TG, Majeed T, Lavelle E, Scott LV, Berti C, Behan P (1997) Blunted serotonin-mediated activation of the hypothalamic–pituitary–adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 22:261–267
Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10:389–398
Capuron L, Pagnoni G, Demetrashvili MF, Lawson DH, Fornwalt FB, Woolwine B et al (2007) Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 32:2384–2392
Zhu CB, Blakely RD, Hewlett WA (2006) The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31:2121–2131
Shanks N, Harbuz MS, Jessop DS, Perks P, Moore PM, Lightman SL (1998) Inflammatory disease as chronic stress. Ann N Y Acad Sci 840:599–607
Del Priore G, Gurski KJ, Warshal DP, Angel C, Dubeshter B (1995) Adrenal function following high-dose steroids in ovarian cancer patients. Gynecol Oncol 59:102–104
Morrow GR, Hickok JT, Andrews PL, Stern RM (2002) Reduction in serum cortisol after platinum based chemotherapy for cancer: a role for the HPA axis in treatment-related nausea? Psychophysiology 39:491–495
Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Lange M, Poulse HS, Müller J (2003) Assessment of the hypothalamus-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumour. J Clin Endocrinol Metab 88:3149–3154
Cleare AJ (2003) The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 24:236–252
Petrovsky N, McNair P, Harrison LC (1998) Diurnal rhythms of proinflammatory cytokines: regulation by plasma cortisol and therapeutic implications. Cytokine 10:307–312
Vgontzas AN, Chrousos GP (2002) Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 31:15–36
McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB (1995) Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 52:89–99
Sephton S, Spiegel D (2003) Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 17:321–328
Bower JE, Ganz PA, Dickerson SS, Dickerson SS, Petersen L, Aziz N et al (2005) Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 30:92–100
Berger AM (1998) Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 25:51–62
Mormont MC, Hecquet B, Bogdan A, Benavides M, Touitou Y, Levi F (1998) Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer 78:421–424
Giordano A, Calvani M, Petillo O, Carteni' M, Melone MR, Peluso G (2003) Skeletal muscle metabolism in physiology and in cancer disease. J Cell Biochem 90:170–186
Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142
Allman BL, Rice CL (2002) Neuromuscular fatigue and aging: central and peripheral factors. Muscle Nerve 25:785–796
Petrella JK, Kim JS, Tuggle SC, Hall SR, Bamman MM (2005) Age differences in knee extension power, contractile velocity, and fatigability. J Appl Physiol 98:211–220
Wilson MM, Morley JE (2003) Invited review: aging and energy balance. J Appl Physiol 95:1728–1736
Dantzer R (2001) Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 933:222–234
Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605–1621
Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D et al (2003) A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 100:1920–1925
Dunn AJ, Wang J, Ando T (1999) Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 461:117–127
Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN et al (2005) Catecholamine mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience 135:1295–1307
Bower JE, Ganz PA, Irwin MR, Arevalo JM, Cole SW (2011) Fatigue and gene expression in human leukocytes: increased NF-κB and decreased glucocorticoid signalling in breast cancer survivors with persistent fatigue. Brain Behav Immun 25:147–150
Luciani A, Jacobsen PB, Extermann M, Foa P, Marussi D, Overcash JA et al (2008) Fatigue and functional dependence in older cancer patients. Am J Clin Oncol 31:424–430
Butt Z, Rao AV, Lai JS, Abernethy AP, Rosenbloom SK, Cella D (2010) Age-associated differences in fatigue among patients with cancer. J Pain Symptom Manage 40:217–223
Bergman H, Ferrucci L, Guralnik J, Hogan DB, Hummel S, Karunananthan S et al (2007) Frailty: an emerging research and clinical paradigm—issues and controversies. J Gerontol A Biol Sci Med Sci 62:731–737
Buchner DM, Wagner EH (1992) Preventing frail health. Clin Geriatr Med 8:1–17
Fried LP, Walston J (2003) Frailty and failure to thrive. In: Hazzard WR, Blass JP, Ettinger WH (eds) Principles of geriatric medicine and gerontology. McGraw-Hill, New York, pp 1487–1502
Siegel K, Lekas HM, Maheshwari D (2012) Causal attributions for fatigue by older adults with advanced cancer. J Pain Symptom Manage 44:52–63
Giacalone A, Blandino M, Talamini R, Bortolus R, Spazzapan S, Valentini M et al (2007) What elderly cancer patients want to know? Differences among elderly and young patients. Psycho-Oncology 16:365–370
Wu HS, McSweeney M (2001) Measurement of fatigue in people with cancer. Oncol Nurs Forum 28:1371–1384
Minton O, Stone P (2009) A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 20:17–25
Yellen SB, Cella DF, Webster K, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63–74
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
Knobel H, Loge JH, Brenne E, Fayers P, Hjermstad MJ, Kaasa S (2003) The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med 17:664–672
Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337–344
Giacalone A, Talamini R, Spina M, Fratino L, Spazzapan S, Tirelli U (2008) Can the caregiver replace his/her elderly cancer patient in the physician–patient line of communication? Support Care Cancer 16:1157–1162
Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC (2011) Psycho-stimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage 41:761–767
Barsevick AM, Dudley W, Beck S, Sweeney C, Whitmer K, Nail L (2004) A randomized clinical trial of energy conservation for patients with cancer-related fatigue. Cancer 100:1302–1310
Graydon JE, Bubela N, Irvine D, Vincent L (1995) Fatigue-reducing strategies used by patients receiving treatment for cancer. Cancer Nurs 18:23–28
Cramp F, Daniel J (2008) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev CD006145
Dimeo FC (2001) Effects of exercise on cancer-related fatigue. Cancer 92:1689–1693
Mock V, Frangakis C, Davidson NE, Ropka ME, Pickett M, Poniatowski B et al (2005) Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncol 14:464–477
Kangas M, Bovbjerg DH, Montgomery GH (2008) Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull 134:700–741
Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G (2009) Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev CD006953
Jacobsen PB, Donovan KA, Vadaparampil ST, Small BJ (2007) Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol 26:660–667
Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C et al (2005) Study of etanercept, a tumour necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 23:5950–5959
Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K et al (2004) A phase II study of etanercept (Enbrel), a tumour necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 10:6528–6534
Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA et al (2006) Assessment of tumour necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 24:1852–1859
Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PL, Flynn PJ et al (2003) Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Centre Community Clinical Oncology Program. J Clin Oncol 21:4635–4641
Kuipers SD, Bramham CR (2006) Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel 9:580–586
Kerr CW, Drake J, Milch RA, Brazeau DA, Skretny JA, Brazeau GA et al (2012) Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 43:68–77
Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ et al (2010) Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-No5C7 Trial. J Clin Oncol 28:3673–3679
Yennurajalingam S, Palmer JL, Chacko R, Bruera E (2011) Factor associated with response to methylphenidate in advanced cancer patients. Oncologist 16:246–253
Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z et al (2009) Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38:650–662
Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Beunis H, Braganza S et al (2008) A randomized, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16:577–583
Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M et al (2010) A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116:3513–3520
Blackhall L, Petroni G, Shu J, Baum L, Farace E (2009) A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. J Palliat Med 12:433–439
Spatis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K (2009) Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 23:325–331
Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J et al (2009) L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage 37:622–631
Esquedo G, Llorca C, Cervera JM, Orts D, Juárez A, Carrato A (2011) Effectiveness of darbepoetin alfa in a color of oncology patients with chemotherapy-induced anemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in hemoglobin level. Clin Transl Oncol 13:341–347
Acknowledgments
The authors wish to thank Mrs Anna Vallerugo, MA, for her linguistic help in preparing the text.
Conflict of interest
The authors have declared no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Rights and permissions
About this article
Cite this article
Giacalone, A., Quitadamo, D., Zanet, E. et al. Cancer-related fatigue in the elderly. Support Care Cancer 21, 2899–2911 (2013). https://doi.org/10.1007/s00520-013-1897-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-013-1897-1